The wave of corporate mergers and acquisitions is poised to accelerate in the second half of 2026, as companies sitting on record cash reserves seek growth through consolidation in an environment where organic expansion has become increasingly difficult.
Deal Volume Rebounds
Global M&A activity reached $1.8 trillion in the first half of 2026, a 27% increase over the same period last year, according to Dealogic. The rebound follows two subdued years during which high interest rates, regulatory uncertainty, and valuation disagreements between buyers and sellers dampened deal-making.
Several factors are driving the resurgence. Corporate balance sheets are strong, with non-financial S&P 500 companies holding a combined $2.4 trillion in cash and short-term investments. Private equity firms are sitting on $1.7 trillion in uninvested capital, or “dry powder,” creating intense pressure to deploy funds before investment periods expire.
Technology and Healthcare Lead
The technology sector has generated the largest deals, led by the trend toward AI-driven consolidation. Companies with proprietary datasets, specialized AI talent, or purpose-built computing infrastructure have become prime acquisition targets. Twelve technology deals valued at more than $5 billion each were announced in the first half alone.
Healthcare M&A has been equally active, driven by pharmaceutical companies seeking to replenish their drug pipelines ahead of major patent expirations. The industry faces a $200 billion revenue cliff between 2026 and 2030 as blockbuster drugs lose exclusivity, making acquisitions of innovative biotech firms strategically essential.
The Regulatory Environment
The antitrust landscape remains a critical variable. The Federal Trade Commission and Department of Justice have signaled continued scrutiny of large horizontal mergers, particularly in technology and healthcare. However, the regulatory stance on vertical mergers and acquisitions by non-dominant players has become somewhat more permissive, opening up opportunities for mid-market deals.
“Companies are structuring transactions to anticipate regulatory challenges rather than hoping to overcome them after the fact,” said Jennifer Liu, co-head of M&A at Lazard. “We are seeing more divestitures offered proactively and more creative deal structures designed to address competitive concerns upfront.”
Cross-Border Deals Face Headwinds
Cross-border acquisitions face additional hurdles from national security reviews. The Committee on Foreign Investment in the United States has expanded its scope, and similar bodies in Europe and Asia have become more active. Technology transfers, access to personal data, and proximity to critical infrastructure are all potential triggers for extended review or outright prohibition.
Despite these challenges, deal advisors expect the M&A boom to continue into 2027. The combination of strategic imperatives, available capital, and narrowing valuation gaps between buyers and sellers suggests that corporate consolidation will remain a defining feature of the business landscape for the foreseeable future.
